Abstracts (HTML) List of Authors

Adamovic, I

1 Case report: Major depression and Therapeutic Drug Monitoring in patient with CYP2C19 genetic polymorphism
2 Drug interactions in patients undergoing opioid maintenance therapy

Adli, M

5 Course of tranylcypromine enantiomer plasma concentrations in patients with depression

Alferink, J

24 Clinical validation study to derive conversion factors from capillary blood concentration to plasma concentration for venlafaxine and desvenlafaxine

Augustin, M

3 Therapeutic Drug Monitoring of antiepileptics and mood stabilizers in pregnancy and lactation

Baumann, P

4 Slow-drop infusion versus oral administration of citalopram: Comparison of plasma concentrations of the enantiomers of citalopram and its metabolites

Bekier, NK

12 Therapeutic Drug Monitoring in the relapse prevention treatment of alcohol dependence

Binder, L

1 Case report: Major depression and Therapeutic Drug Monitoring in patient with CYP2C19 genetic polymorphism

Bleich, S

26 Current data from the AMSP Project on the risk of treatment with antidepressants and antipsychotics within the clinical setting

Boettcher, M

2 Drug interactions in patients undergoing opioid maintenance therapy

Breisinger, S

21 Therapeutic drug monitoring of antidepressants in chronic pain treatment

Brune, S

16 Using physiologically based pharmacokinetic (PBPK) modelling and SCHOLZ databank’s MDDI calculator (SDB-MDDI) to predict potential drug-drug interactions (DDI) of psychopharmaceuticals

Buspavanich, P

5 Course of tranylcypromine enantiomer plasma concentrations in patients with depression

Clement, HW

19 Therapeutic Reference Ranges of Cariprazine and Atomoxetine

Deckert, J

21 Therapeutic drug monitoring of antidepressants in chronic pain treatment

Degner, D

1 Case report: Major depression and Therapeutic Drug Monitoring in patient with CYP2C19 genetic polymorphism

Egberts, K

6 A multicenter pharmacovigilance study on antidepressant and antipsychotic use in children and adolescents in daily clinical practice
8 Serum concentrations of venlafaxine and risperidone and their metabolites from childhood to old age

Endres, K

7 The dose-related reference range – a new approach with improved predictive quality

Fekete, S

6 A multicenter pharmacovigilance study on antidepressant and antipsychotic use in children and adolescents in daily clinical practice
8 Serum concentrations of venlafaxine and risperidone and their metabolites from childhood to old age

Fey, T

24 Clinical validation study to derive conversion factors from capillary blood concentration to plasma concentration for venlafaxine and desvenlafaxine

Fischer, M

21 Therapeutic drug monitoring of antidepressants in chronic pain treatment

Fleischhaker, C

19 Therapeutic Reference Ranges of Cariprazine and Atomoxetine

Geiben, A

9 Influence of comedication on amitriptyline underscore the necessity of TDM

Geiben, AK

16 Using physiologically based pharmacokinetic (PBPK) modelling and SCHOLZ databank’s MDDI calculator (SDB-MDDI) to predict potential drug-drug interactions (DDI) of psychopharmaceuticals

Gerlach, M

6 A multicenter pharmacovigilance study on antidepressant and antipsychotic use in children and adolescents in daily clinical practice
8 Serum concentrations of venlafaxine and risperidone and their metabolites from childhood to old age

Giebels, M

24 Clinical validation study to derive conversion factors from capillary blood concentration to plasma concentration for venlafaxine and desvenlafaxine

Grohmann, R

26 Current data from the AMSP Project on the risk of treatment with antidepressants and antipsychotics within the clinical setting

Gründer, G

10 How valid are therapeutic reference ranges for psychotropic drugs?
22 Using TDM to improve efficacy and safety outcomes of antipsychotic treatment

Haen, E

15 A HPLC-UV/VIS method for the quantification of valproic acid in human serum
9 Influence of comedication on amitriptyline underscore the necessity of TDM
7 The dose-related reference range – a new approach with improved predictive quality
22 Using TDM to improve efficacy and safety outcomes of antipsychotic treatment

Hart, XM

10 How valid are therapeutic reference ranges for psychotropic drugs?

Havemann-Reinecke, U

2 Drug interactions in patients undergoing opioid maintenance therapy

Hefner, G

11 Psychopharmacotherapy in geriatric patients

Hempel, G

16 Using physiologically based pharmacokinetic (PBPK) modelling and SCHOLZ databank’s MDDI calculator (SDB-MDDI) to predict potential drug-drug interactions (DDI) of psychopharmaceuticals
14 Physiologically based pharmacokinetic modelling of risperidone and 9-hydroxyrisperidone to determine cytochrome P450 2D6 phenotypes in schizophrenia patients
24 Clinical validation study to derive conversion factors from capillary blood concentration to plasma concentration for venlafaxine and desvenlafaxine

Hiemke, C

12 Therapeutic Drug Monitoring in the relapse prevention treatment of alcohol dependence
10 How valid are therapeutic reference ranges for psychotropic drugs?
2 Drug interactions in patients undergoing opioid maintenance therapy
22 Using TDM to improve efficacy and safety outcomes of antipsychotic treatment

Hindinger, C

5 Course of tranylcypromine enantiomer plasma concentrations in patients with depression

Kiefer, F

12 Therapeutic Drug Monitoring in the relapse prevention treatment of alcohol dependence

Kittel-Schneider, S

13 Therapeutic drug monitoring in pregnancy and post-partum period – antidepressant substances
8 Serum concentrations of venlafaxine and risperidone and their metabolites from childhood to old age

Kneller, LA

14 Physiologically based pharmacokinetic modelling of risperidone and 9-hydroxyrisperidone to determine cytochrome P450 2D6 phenotypes in schizophrenia patients

Lipecki, Y

15 A HPLC-UV/VIS method for the quantification of valproic acid in human serum

Lübking, M

24 Clinical validation study to derive conversion factors from capillary blood concentration to plasma concentration for venlafaxine and desvenlafaxine

Lücht, UR

16 Using physiologically based pharmacokinetic (PBPK) modelling and SCHOLZ databank’s MDDI calculator (SDB-MDDI) to predict potential drug-drug interactions (DDI) of psychopharmaceuticals

Meinzer, S

18 Optimizing Therapeutic Drug Monitoring (TDM) of mirtazapine – Next step to personalized medicine

Michaelis, S

1 Case report: Major depression and Therapeutic Drug Monitoring in patient with CYP2C19 genetic polymorphism

Molden, E

17 Using TDM data to study treatment failure

Musil, R

18 Optimizing Therapeutic Drug Monitoring (TDM) of mirtazapine – Next step to personalized medicine

Nierychlewski, K

18 Optimizing Therapeutic Drug Monitoring (TDM) of mirtazapine – Next step to personalized medicine

Nil, R

4 Slow-drop infusion versus oral administration of citalopram: Comparison of plasma concentrations of the enantiomers of citalopram and its metabolites

Oster, O

19 Therapeutic Reference Ranges of Cariprazine and Atomoxetine

Paulzen, M

22 Using TDM to improve efficacy and safety outcomes of antipsychotic treatment

Plener, P

6 A multicenter pharmacovigilance study on antidepressant and antipsychotic use in children and adolescents in daily clinical practice

Preis, K

13 Therapeutic drug monitoring in pregnancy and post-partum period – antidepressant substances

Ricken, R

5 Course of tranylcypromine enantiomer plasma concentrations in patients with depression

Rittner, HL

21 Therapeutic drug monitoring of antidepressants in chronic pain treatment

Roll, SC

20 The relevance of TDM in opiate withdrawal

Romanos, M

6 A multicenter pharmacovigilance study on antidepressant and antipsychotic use in children and adolescents in daily clinical practice
8 Serum concentrations of venlafaxine and risperidone and their metabolites from childhood to old age

Ruppert, K

19 Therapeutic Reference Ranges of Cariprazine and Atomoxetine

Scherf-Clavel, M

21 Therapeutic drug monitoring of antidepressants in chronic pain treatment
8 Serum concentrations of venlafaxine and risperidone and their metabolites from childhood to old age

Scholz, WU

16 Using physiologically based pharmacokinetic (PBPK) modelling and SCHOLZ databank’s MDDI calculator (SDB-MDDI) to predict potential drug-drug interactions (DDI) of psychopharmaceuticals

Schoretsanitis, G

22 Using TDM to improve efficacy and safety outcomes of antipsychotic treatment

Schulz, E

19 Therapeutic Reference Ranges of Cariprazine and Atomoxetine

Schwarz, M

18 Optimizing Therapeutic Drug Monitoring (TDM) of mirtazapine – Next step to personalized medicine

Shipkova, M

23 Liquid Chromatography/Tandem Mass Spectrometry (LC-MSMS) Analysis of neuropsychiatric drugs: Challenges from the perspective of the laboratory physician

Stern, M

24 Clinical validation study to derive conversion factors from capillary blood concentration to plasma concentration for venlafaxine and desvenlafaxine

Stingl, JC

25 Pharmacogenetic diagnostics and therapeutic implications for genome medicine

Streit, F

1 Case report: Major depression and Therapeutic Drug Monitoring in patient with CYP2C19 genetic polymorphism

Taurines, R

6 A multicenter pharmacovigilance study on antidepressant and antipsychotic use in children and adolescents in daily clinical practice

TDM-VIGIL-Consortium,

6 A multicenter pharmacovigilance study on antidepressant and antipsychotic use in children and adolescents in daily clinical practice

Toto, S

26 Current data from the AMSP Project on the risk of treatment with antidepressants and antipsychotics within the clinical setting

Ulrich, S

5 Course of tranylcypromine enantiomer plasma concentrations in patients with depression

Unterecker, S

21 Therapeutic drug monitoring of antidepressants in chronic pain treatment
13 Therapeutic drug monitoring in pregnancy and post-partum period – antidepressant substances
8 Serum concentrations of venlafaxine and risperidone and their metabolites from childhood to old age

van Braam, L

13 Therapeutic drug monitoring in pregnancy and post-partum period – antidepressant substances

Vierke, C

2 Drug interactions in patients undergoing opioid maintenance therapy

Zurek, G

27 Comparative study of suggested reference values and observed distributions in daily routine of a medical laboratory – lessons learned and open questions